The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.

Destiny's IPO gives it £15.3 million to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.

Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.

Corporate venture capital has long been an important source of capital for early-stage biotechs and shows no signs of diminishing.

The West Coast biotech signed up new Chinese backers to expand its late-phase immuno-oncology program and move an anti-PD-1 antibody into the clinic.

After nearly a year and three term revisions, Accelerated Pharma is pulling its initial public offering.

MabVax Therapeutics is hiring an investment bank to help it find a buyer or sell off its assets as it continues to struggle for cash.

The financing gives Laura Deming, who started work on the fund before turning 18, $22 million to invest in companies working on age-related diseases.

Venture Capital